Want to reduce the risk of obesity-related complications? (ATTAIN NOW)

The ATTAIN NOW Trial

If you are 18 years of age or older, are overweight (BMI >26) without type 2 diabetes, and have certain health conditions that may increase your risk of obesity-related complications (ORCs), you may qualify for a clinical trial evaluating a once daily medication which may help with weight loss

The ATTAIN-NOW clinical trial, sponsored by Eli Lilly, is evaluating orforglipron vs. placebo, in addition to lifestyle intervention. The study medication will be provided at no cost to qualifying participants.

The study is enrolling adults who are at risk of ORCs, including those with:

• Prediabetes
• Prehypertension or high-normal blood pressure
• Predyslipidemia

The primary objective of the study is to determine whether treatment with orforglipron, compared with placebo, can reduce the risk of obesity-related complications or the development of Class 1 obesity. The study is 156 weeks long.

If you're worried about obesity-related complications developing and would like to learn more about the ATTAIN-NOW clinical trial, contact us to see if you may qualify and are eligible to participate.

To learn more, please email Yweight@yale.edu and provide the best phone number to reach you.